I don't think that necessarily answers my question.
Do you have any sensitivity analysis or otherwise done that factors in higher spodumene prices, and how a lower production volume would affect overall EBITDA?
All Li shares are down across the board 20 - 25% from their all time highs, I don't think we can pin the SP purely on the quarterly announcement. To me this is more general market weakness than company specific performance.
Good News & Bad News, page-8217
-
- There are more pages in this discussion • 36,406 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.87 |
Change
-0.020(0.69%) |
Mkt cap ! $8.638B | |||
| Open | High | Low | Value | Volume |
| $2.79 | $2.92 | $2.78 | $84.74M | 29.64M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 173645 | $2.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.88 | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| PLS (ASX) Chart |